From Yahoo Finance: 2025-05-29 23:29:00

Pfizer Inc. (PFE) ends partnership with Acepodia as it faces lawsuits over Depo-Provera contraceptive. Decision attributed to global resource prioritization, not Acepodia’s capabilities. Wind-down won’t impact Acepodia’s clinical programs, leaving open possibility of future collaboration.

Pfizer Inc. (PFE) embroiled in multidistrict litigation over Depo-Provera, facing 400 lawsuits alleging failure to warn about brain tumor risks. Company accused of prioritizing profits over patient safety. Despite challenges, PFE’s performance stable but investor sentiment cautious. Share price reflects uncertainties, with marginal upside projected.

Analysts note Pfizer Inc. (PFE) underperformed US pharmaceutical sector, with total shareholder return falling 11.11% in past year. Future earnings and revenue growth crucial for outlook. While PFE has potential to grow, some believe AI stocks offer higher returns with limited downside risk. Check out report on promising AI stock.

Read more: Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes